Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial

Lancet

Volumn 364, Issue 9440, 2004, Pages 1127-1134

  Verweij, Jaap ^a   Casali, Paolo G ^b   Zalcberg, John ^c   LeCesne, Axel ^d   Reichardt, Peter ^e   Blay, Jean Yves ^f   Issels, Rolf ^g   Van Oosterom, Allan ^h   Hogendoorn, Pancras C W ⁱ   Van Glabbeke, Martine ^j   Bertulli, Rossella ^l   Judson, Ian ^k  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Instituto Tumori   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Helios Klinikum   (Germany)

^f INSERM   (France)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j EORTC DATA CENTER   (Belgium)

^k ROYAL MARSDEN HOSPITAL   (United Kingdom)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LETHARGY; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PLEURAL PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; UROGENITAL TRACT DISEASE; VOMITING;

EID: 20844433223     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17098-0     Document Type: Article

References (17)

1. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors: a review. Acta Orthop Scand Suppl. 75:2004;62-71
2. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 33:2002;478-483
3. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 54:2001;96-102
4. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 33:2002;459-465
5. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3:2002;655-664
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580
7. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358:2001;1421-1423
8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:2002;472-480
9. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 39:2003;2006-2011
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:2000;205-216
11. Kalbfleisch JD, Prentice RL. Statistical analysis of failure time data. 1980;163-178 Wiley, New York
12. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154
13. Hommel GA. stagewise rejective multiple test procedure bases on a modified Bonferroni test. Biometrika. 75:1988;383-386
14. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib in patients with metastatic GIST: phase III sarcoma group study S0033. Proc ASCO. 23:2004;815
15. Judson IR, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour a retrospective population pharmacokinetic study over time. Cancer Chemother Pharmacol (in press).
16. Blay JY, Berthaud P, Perol D, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Proc ASCO. 23:2004;815
17. Zalcberg JR, Verweij J, Casali P, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg after progression on 400 mg: an international intergroup study of the EORTC, ISG and AGITG. Proc ASCO. 23:2004;815